NCT00840827View on ClinicalTrials.gov

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

lenalidomide

Lenalidomide 10mg po daily

DRUG

cyclosporine A

CSA 250mg orally twice daily

Trial Locations (1)

10021

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER